GlassScriptPhysician profile
Jeffrey A Rother
NPI 1811951999
$4,592.03
in general payments reported to CMS, 2019-2025
32 companies · $601 in 2025
The $601 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $154 · 2021: $415 · 2022: $1,054 · 2023: $939 · 2024: $975 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,515.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $603.11 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $548.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $544.37 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Sanofi-Aventis U.S. LLC | $540.37 | 2019-2023 | |
| Glaxosmithkline, LLC. | $540.24 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $316.15 | 2021-2025 | |
| Insulet Corporation | $234.22 | 2024 | Omnipod |
| Janssen Pharmaceuticals, INC | $132.50 | 2019-2024 | Spravato |
| Abbvie INC. | $118.71 | 2022-2025 | Ubrelvy |
| Xeris Pharmaceuticals, INC. | $110.24 | 2021-2023 | Keveyis |
| Merck Sharp & Dohme LLC | $99.48 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.15 | 2022-2025 | Jardiance |
| Pfizer INC. | $79.06 | 2019-2024 | |
| Amgen INC. | $77.21 | 2021-2024 | Evenity, Prolia, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $64.69 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $54.36 | 2019-2024 | Freestyle Libre 3 |
| Halozyme INC | $53.26 | 2023 | |
| Phathom Pharmaceuticals, INC. | $48.99 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.43 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $36.31 | 2024 | Gemtesa |
| Antares Pharma, INC. | $36.00 | 2024 | Xyosted |
| Mylan Specialty L.P. | $33.52 | 2021-2024 | Yupelri |
| Amarin Pharma, INC. | $32.22 | 2019 | |
| Exact Sciences Corporation | $30.06 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $24.94 | 2019 | |
| Astellas Pharma US INC | $17.63 | 2021 | |
| Averitas Pharma INC. | $17.19 | 2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $15.45 | 2023 | |
| Genentech USA, INC. | $14.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.93 | 2023 | Austedo |
| Dexcom, INC. | $12.83 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rother listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.